{"id":"https://openalex.org/W4389480896","doi":"https://doi.org/10.1016/j.iotech.2023.100611","title":"139P Safety and clinical activity of a novel anti-CCR8 antibody (LM-108) as a single agent or in combination with pembrolizumab in patients with advanced solid tumors: Results of phase I study","display_name":"139P Safety and clinical activity of a novel anti-CCR8 antibody (LM-108) as a single agent or in combination with pembrolizumab in patients with advanced solid tumors: Results of phase I study","publication_year":2023,"publication_date":"2023-12-01","ids":{"openalex":"https://openalex.org/W4389480896","doi":"https://doi.org/10.1016/j.iotech.2023.100611"},"language":"en","primary_location":{"id":"doi:10.1016/j.iotech.2023.100611","doi":"https://doi.org/10.1016/j.iotech.2023.100611","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.iotech.2023.100611","pdf_url":"http://www.esmoiotech.org/article/S2590018823002745/pdf","source":{"id":"https://openalex.org/S4210240197","display_name":"Immuno-Oncology Technology","issn_l":"2590-0188","issn":["2590-0188"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","norway-1","poland-20"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Immuno-Oncology and Technology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"http://www.esmoiotech.org/article/S2590018823002745/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5110147506","display_name":"Alexander Starodub","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210134025","display_name":"Christ Hospital","ror":"https://ror.org/03dm2se39","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210134025"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. Starodub","raw_affiliation_strings":["Oncology, The Christ Hospital - Hematology & Oncology, Cincinnati, OH, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, The Christ Hospital - Hematology & Oncology, Cincinnati, OH, USA","institution_ids":["https://openalex.org/I4210134025"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079022151","display_name":"Mateusz Opyrchal","orcid":"https://orcid.org/0000-0003-2454-7441","observed_orcids":["https://orcid.org/0000-0003-2454-7441"]},"institutions":[{"id":"https://openalex.org/I4388446366","display_name":"Indiana University Indianapolis","ror":"https://ror.org/03eftgw80","country_code":"US","type":"education","lineage":["https://openalex.org/I4388446366","https://openalex.org/I592451"]},{"id":"https://openalex.org/I4394709130","display_name":"Indiana University School of Medicine","ror":"https://ror.org/02ets8c94","country_code":"US","type":"education","lineage":["https://openalex.org/I4394709130","https://openalex.org/I592451"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. Opyrchal","raw_affiliation_strings":["School of Medicine, Indiana University, Indianapolis, IN USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"School of Medicine, Indiana University, Indianapolis, IN USA","institution_ids":["https://openalex.org/I4388446366","https://openalex.org/I4394709130"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104124681","display_name":"Rama Balaraman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. Balaraman","raw_affiliation_strings":["Hematology and Oncology, Florida Cancer Affiliates, Ocala, FL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology and Oncology, Florida Cancer Affiliates, Ocala, FL, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015591858","display_name":"Minal A. Barve","orcid":"https://orcid.org/0009-0007-4259-7457","observed_orcids":["https://orcid.org/0009-0007-4259-7457"]},"institutions":[{"id":"https://openalex.org/I4210087725","display_name":"Mary Crowley Cancer Research Center","ror":"https://ror.org/002ksg449","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210087725"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. Barve","raw_affiliation_strings":["Oncology, Mary Crowley Cancer Research Center, Dallas, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, Mary Crowley Cancer Research Center, Dallas, TX, USA","institution_ids":["https://openalex.org/I4210087725"]}]},{"author_position":"middle","author":{"id":null,"display_name":"D. Fei","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. Fei","raw_affiliation_strings":["Medical Science, LaNova Medicines, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Science, LaNova Medicines, Shanghai, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100385080","display_name":"Rong Li","orcid":"https://orcid.org/0000-0003-3971-1670","observed_orcids":["https://orcid.org/0000-0003-3971-1670"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. Li","raw_affiliation_strings":["Discovery, LaNova Medicines, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Discovery, LaNova Medicines, Shanghai, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"T. Bai","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T. Bai","raw_affiliation_strings":["Medical Science, LaNova Medicines, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Science, LaNova Medicines, Shanghai, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"L. Kong","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L. Kong","raw_affiliation_strings":["Clinical Operation, LaNova Medicines, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Operation, LaNova Medicines, Shanghai, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101593272","display_name":"Xue Ying Qin","orcid":"https://orcid.org/0000-0002-4513-3515","observed_orcids":["https://orcid.org/0000-0002-4513-3515"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"X. Qin","raw_affiliation_strings":["Medical Science, LaNova Medicines, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Science, LaNova Medicines, Shanghai, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"C. Qin","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. Qin","raw_affiliation_strings":["Oncology, LaNova Medicines, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, LaNova Medicines, Shanghai, China","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5090621600","display_name":"Abdul Rafeh Naqash","orcid":"https://orcid.org/0000-0001-7622-720X","observed_orcids":["https://orcid.org/0000-0001-7622-720X"]},"institutions":[{"id":"https://openalex.org/I4390039271","display_name":"OU Health","ror":"https://ror.org/00a6cxf28","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4390039271"]},{"id":"https://openalex.org/I4390039380","display_name":"OU Health Stephenson Cancer Center","ror":"https://ror.org/02bmcqd02","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4390039271","https://openalex.org/I4390039380"]},{"id":"https://openalex.org/I49332381","display_name":"University of Oklahoma Health Sciences Center","ror":"https://ror.org/0457zbj98","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I49332381"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A-R. Naqash","raw_affiliation_strings":["Oncology, Stephenson Cancer Center, Oklahoma University Health Science Center, Oklahoma City, OK, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology, Stephenson Cancer Center, Oklahoma University Health Science Center, Oklahoma City, OK, USA","institution_ids":["https://openalex.org/I4390039271","https://openalex.org/I4390039380","https://openalex.org/I49332381"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":7,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3020,"currency":"USD","value_usd":3020},"apc_paid":{"value":3020,"currency":"USD","value_usd":3020},"fwci":0.1216,"has_fulltext":true,"cited_by_count":1,"citation_normalized_percentile":{"value":0.46858693,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":90,"max":94},"biblio":{"volume":"20","issue":null,"first_page":"100611","last_page":"100611"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9911999702453613,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9911999702453613,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.003700000001117587,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0012000000569969416,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ccr8","display_name":"CCR8","score":0.7440000176429749},{"id":"https://openalex.org/keywords/tumor-infiltrating-regulatory-t-cells","display_name":"tumor-infiltrating regulatory T cells","score":0.9120000004768372},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9679999947547913},{"id":"https://openalex.org/keywords/anti-pd-1-combination-therapy","display_name":"anti-PD-1 combination therapy","score":0.7850000262260437},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.9440000057220459},{"id":"https://openalex.org/keywords/antibody-dependent-cellular-cytotoxicity","display_name":"antibody-dependent cellular cytotoxicity","score":0.8489999771118164},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.8130000233650208},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.5929999947547913},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.671999990940094},{"id":"https://openalex.org/keywords/first-in-human","display_name":"first-in-human","score":0.6359999775886536}],"concepts":[{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.8478648662567139},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7844680547714233},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.7647603750228882},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.7500574588775635},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6049426198005676},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5329146385192871},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.4715476334095001},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4069664776325226},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3636380732059479},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.34293484687805176},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.26801708340644836},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.2450409233570099},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.22768327593803406}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.iotech.2023.100611","doi":"https://doi.org/10.1016/j.iotech.2023.100611","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.iotech.2023.100611","pdf_url":"http://www.esmoiotech.org/article/S2590018823002745/pdf","source":{"id":"https://openalex.org/S4210240197","display_name":"Immuno-Oncology Technology","issn_l":"2590-0188","issn":["2590-0188"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","norway-1","poland-20"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Immuno-Oncology and Technology","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1016/j.iotech.2023.100611","doi":"https://doi.org/10.1016/j.iotech.2023.100611","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.iotech.2023.100611","pdf_url":"http://www.esmoiotech.org/article/S2590018823002745/pdf","source":{"id":"https://openalex.org/S4210240197","display_name":"Immuno-Oncology Technology","issn_l":"2590-0188","issn":["2590-0188"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","norway-1","poland-20"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Immuno-Oncology and Technology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4389480896.pdf","grobid_xml":"https://content.openalex.org/works/W4389480896.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4410812614","https://openalex.org/W7154741988","https://openalex.org/W4410816474","https://openalex.org/W4404554361","https://openalex.org/W4393989344","https://openalex.org/W4365513359","https://openalex.org/W4404067293","https://openalex.org/W4402561232","https://openalex.org/W4282966198","https://openalex.org/W7154701153"],"abstract_inverted_index":{"Tumor-infiltrating":[0],"regulatory":[1],"T":[2],"cells":[3,23],"(TITR)":[4],"specifically":[5],"demonstrate":[6],"high":[7],"expression":[8],"of":[9,73,126,150,153,162,219,242,254,267],"chemokine":[10],"receptor":[11],"8":[12],"(CCR8).":[13],"LM-108":[14,29,53,118,154,272],"is":[15],"an":[16],"anti-CCR8":[17],"monoclonal":[18],"antibody":[19,36],"that":[20],"deplete":[21],"TITR":[22],"with":[24,34,60,64,90,156,237,277,289],"enhanced":[25],"antibody-dependent":[26],"cell-mediated":[27],"cytotoxicity.":[28],"alone":[30],"or":[31,57,100,108,188,274],"in":[32,44,58,62,186,275,287],"combination":[33,59,174,189,259,276],"anti-PD-1":[35],"has":[37],"demonstrated":[38],"excellent":[39,280],"activity":[40,286],"and":[41,135,171,211,230,248,283],"safety":[42,281],"profile":[43,282],"animal":[45],"models.":[46],"This":[47,77],"phase":[48,74,81],"1/2":[49,82],"study":[50,83,204],"(NCT05255484)":[51],"evaluate":[52],"as":[54,138],"single":[55],"agent":[56],"pembrolizumab":[61,159,278],"patients":[63,85,167,221,232,257,264,288],"advanced":[65,91,290],"solid":[66,92,291],"tumor.":[67],"Here,":[68],"we":[69],"present":[70],"the":[71,104,203],"results":[72],"1":[75,129,215,224],"part.":[76],"first-in-human,":[78],"multicenter,":[79],"open-label,":[80],"enrolled":[84],"aged":[86],"\u2265":[87],"18":[88],"years":[89],"tumors":[93],"who":[94],"had":[95,109,265],"progressed":[96],"on":[97],"standard":[98,106,112],"therapy,":[99,107],"were":[101,119,176,206],"intolerable":[102],"to":[103,202],"available":[105,111],"no":[110,178],"therapy":[113,144],"for":[114],"treatment.":[115],"For":[116],"monotherapy,":[117,223],"administered":[120],"intravenously":[121],"Q3W":[122],"at":[123,147,182],"dose":[124,148,184],"levels":[125,185],"0.3":[127],"mg/kg,":[128,130,132,134],"3":[131,172],"10":[133,151],"20":[136],"mg/kg":[137,152],"per":[139],"traditional":[140],"3+3":[141],"design.":[142],"Combination":[143],"was":[145,180,192],"evaluated":[146],"level":[149],"combined":[155],"200":[157],"mg":[158],"Q3W.":[160],"As":[161],"July":[163],"3,":[164],"2023,":[165],"24":[166],"(21":[168],"from":[169,173,222,258],"monotherapy":[170,187,273],"therapy)":[175],"enrolled,":[177],"DLT":[179],"observed":[181],"all":[183],"therapy.":[190],"MTD":[191],"not":[193],"reached.":[194],"The":[195,261],"most":[196],"frequent":[197],"adverse":[198],"events":[199],"(AEs)":[200],"related":[201],"drug":[205],"rash":[207],"(8/24,":[208],"Grade":[209,216],"1-2)":[210],"diarrhea":[212],"(3/24,":[213],"including":[214],"3).":[217],"Out":[218],"19":[220],"patient":[225,245,250],"achieved":[226,233,246,251],"partial":[227],"response":[228,268],"(PR)":[229],"11":[231],"stable":[234],"disease":[235,239],"(SD)":[236],"a":[238],"control":[240],"rate":[241],"63%.":[243],"One":[244],"PR":[247,263],"one":[249],"SD":[252],"out":[253],"2":[255],"evaluable":[256],"group.":[260],"two":[262],"duration":[266],"over":[269],"6":[270],"months.":[271],"showed":[279],"promising":[284],"anti-tumor":[285],"tumors.":[292]},"counts_by_year":[{"year":2025,"cited_by_count":1}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2023-12-09T00:00:00"}